



Primary Care Respiratory Society Get Winter Wrapped

Peak flow monitoring and microspirometry as aids to respiratory diagnosis in primary care: more important than ever in times of COVID



Duncan Keeley *Executive Committee Member PCRS*

Introduction

Peak flow charting and microspirometry are undervalued in guidelines and were underused in primary care even before the COVID pandemic, but have enhanced importance now given the difficulties with access to more formal respiratory function testing. We should always seek objective physiological confirmation of our diagnosis where possible.

The common chronic respiratory disorders diagnosed in primary care – asthma and COPD (chronic obstructive pulmonary disease) are both characterised by airways obstruction. In asthma this varies markedly with time and treatment while in COPD the airways obstruction is typically fixed and permanent. Some people have fixed obstruction with some degree of reversibility – the so-called asthma COPD overlap syndrome.

Diagnosis involves careful history taking and examination before moving on to physiological testing – being careful to keep in mind other respiratory and non-respiratory diagnoses that may cause breathlessness or cough. The pattern of symptoms over time and their response to treatment is also important, and earlier diagnoses should be re-interrogated if necessary. Always review an initial diagnosis – and consider referral to a specialist – if response to treatment is poor or there are atypical features. Chronic sputum pro-

duction, for example, is highly unusual in asthma and even in COPD should prompt consideration of bronchiectasis. Get a chest X ray at the time of any new diagnosis of COPD, and if apparent asthma has definite atypical features.

Peak flow measurement and microspirometry are themselves both potentially aerosol generating procedures so we need to develop methods for remote teaching of technique and assessment of results – both made eminently possible by the rapid advances in both the availability and the use of digital technologies which have resulted from the pandemic. Video tutorials in using peakflow meters and microspirometers can easily be found online and patients can be directed to these – or better still make you own to add that personal touch. If you do this make sure you check that you have got it right!

This article will cover the use of peak flow monitoring and microspirometry in primary care as aids to the objective demonstration of airways obstruction – reversible or otherwise.

PCRS have published guidance on respiratory diagnosis during the pandemic.¹



Peak Flow Monitoring

The great advantages of peak flow measurement in asthma diagnosis are the low cost and ready availability of the equipment, and the ease with which peak flow measurement – and periods of peak flow monitoring – can be repeated. Measurements can – and should – start at once if a patient presents with acute symptoms.

Repeated measurement and charting of peak expiratory flow has long been used for the diagnosis of asthma. Like many long established and simple aids to diagnosis the published evidence base for its use is surprisingly sparse: a recent assessment for the NICE guideline on asthma diagnosis² cites a generally low and variable sensitivity but a specificity of up to 0.99 in adults and 0.80 in children for peak flow monitoring in the diagnosis of asthma. This high specificity (“negativity in health”) does mean however that clear evidence of peak flow variability is very good for ruling asthma in as a diagnosis, while sensitivity (“positivity in disease”) improves if the monitoring is repeated – particularly across a period of exacerbation and remission of symptoms.

Who should do this?

Setting up peak flow monitoring with a patient suspected of having asthma requires the health professional to have the skills and the time to do it. Just like correct use of an inhaler, teaching correct use of a peak flow meter is not like falling off a log and a surprising number of health professionals don't know how to do it. Learn! It is not rocket science either. Explaining and teaching effective peak flow monitoring does take a bit of time – but attention to correct diagnosis at the outset saves a great deal of time down the line. If there is not time to do the job at the first consultation arrange for review as soon as possible to go over it more thoroughly – but always get at least one peak flow and give them a meter and a chart before starting any treatment.



How to do it


Effective peak flow monitoring for diagnosis depends on:

1. Explaining to the patient or parent how valuable a period of peak flow monitoring is in helping to make a correct diagnosis. “This is a bit of a fuss but it will really help us to get the right diagnosis and get you onto the right treatment and make you better.”
2. Correct teaching of how to use the peak flow meter. Best of three hard fast blows and record the highest reading.
3. Having the patient or parent show you that they can perform peak flow measurements, correctly read the meter and correctly plot that number on a chart. They must be able to do all three to make a meaningful peak flow chart.
4. Taking measurements twice daily, or more – for a sufficient period – usually at least 2-4 weeks – at a time when symptoms are present. Peak flow charting when introducing a trial of treatment is particularly worthwhile. Encourage measurement when symptoms are marked and when they are better. Pre and post exercise readings are also useful.
5. Knowing how to identify abnormal variability in peak flow.
6. Repeating the testing period at a later date if symptoms persist but initial testing is inconclusive or the diagnosis remains in doubt.

Peak expiratory flow (PEF) should be recorded as the best of three forced expiratory blows from total lung capacity with a maximum pause of two seconds before blowing. The patient can be standing or sitting. Further blows should be done if the largest two PEF are not within 40 L/min.

Charts are provided with peak flow meters but these are limited in duration. Drug companies provide peak flow diaries, or you can use the excellent charts in the booklet FP1010 often still available from primary care organisations. Charting the readings on

The brilliant Form FP1010 - contains 32 weeks' worth of PEFR charts, instruction for use and care of the peak flow meter and has space at the back for a written personal action plan



a graph is much preferable to recording numbers only since it allows better pattern recognition and easier identification of maximum and minimum readings. Electronic meters with memory recording exist but are little used outside of research settings. Mobile phone attachment PEFR meters with accompanying apps to record and chart results are becoming available.

The age at which children become able to do reliable peak flow measurements cannot be easily defined – Most children aged 7 years and over will be able to perform meaningful peak flow measurements. Children should be given a low range peak flow meter.

For a patient with acute wheezing that you are planning to treat with high dose bronchodilators and/or oral corticosteroids, always measure peak flow before and after treatment; this is good practice in any case as part of the assessment of severity of the attack and may afterwards provide strong supportive evidence for an asthma diagnosis.

“Poor compliance”

It is often said that compliance with peak flow charting is poor. In my experience, this is not true if the method, purpose and value of the charting is clearly explained and it is made clear that charting does not need to continue once the diagnosis is made. Discussions of peak flow monitoring also sometimes refer to falsification of peak flow records – usually to conceal the fact that the measurements have not actually been done. What is needed is a patient and trusting relationship between health professional and parent or patient. This allows effective explanation of the importance of doing what has been asked – and of being honest if it has not been possible to do this for whatever reason. With experience it is often easy to tell that a record has been made up – and gently share this possibility with the patient. A miniscule

number of patients may deliberately falsify a record to make it appear that they have asthma when they do not. This can be hard to detect but is vanishingly rare.

What is abnormal peak flow variability?

There are a variety of numerical definitions. Like blood pressure and blood glucose, peak flow variability is a continuous physiological variable and cut off points are arbitrary. One commonly used definition (cited in the BTS/SIGN guideline)³ is the difference between maximum and minimum expressed as a percentage of the mean peak flow, with more than 20% being considered abnormal. If the max-min difference is greater than 20% of the maximum reading (easier to find than the mean) then this is clearly abnormal.

As helpful as the numbers is the appearance pattern of the graph. The most typical picture is of low readings with obvious saw tooth variability flattening out and rising as symptoms respond with time or treatment.


The illustration below shows the peak flow chart of a 55 year old never smoker with a one year history of recurrent worsening cough and shortness of breath. His chest X-ray was normal. His symptoms had greatly improved with a one week course of prednisolone but recurred when the steroids were stopped. The chart was done as he started on twice daily inhaled corticosteroids by spacer. It provides convincing objective evidence of significant peak flow variability – coinciding with resolution of his symptoms. This is strongly supportive of an asthma diagnosis.

Remember occupational asthma

The possibility of occupational asthma should be born in mind whenever you make a new asthma diagnosis in an adult. In addition to careful history taking around occupation and symptoms a period of peak flow charting indicating when the patient is at work is vital. Patients in whom occupational asthma is suspected should be referred for specialist assessment but should chart their peak flow until seen.

Does peak flow monitoring have any place in the diagnosis of COPD?

Peak flow measurement is not adequate for definitive COPD diagnosis. This requires quality-assured diagnostic spirometry in addition to a full clinical assessment. But in the pandemic – with limited access to full spirometry – serial PEF measurement can be utilised to help support a provisional diagnosis of COPD.



Two-week peak flow tracing consistent with a diagnosis of asthma: a picture is worth a thousand words

One small study suggested that reduced PEF below 80% predicted was found in 90% of all spirometry confirmed COPD and 100% of severe and very severe COPD.⁴ Lack of variability in 2-3 weeks of PEF readings suggests fixed airways obstruction.

Remember that asthma can develop at any age, and if late onset asthma (or COPD with a substantial reversible component) is suspected then peak flow charting is valuable.

Any COPD diagnosis made without full diagnostic spirometry should be flagged in the records as provisional.

Do patients with asthma need to continue to monitor their peak flow?

Usually not. But it is worth keeping their peak flow meter and knowing their best and lowest readings. Restarting peak flow measurements may be useful for some people as part of a personal asthma action plan. Most patients can effectively self-manage based on symptoms alone – but some are slow to recognise significant deteriorations (“poor symptom perceivers”) and they may find regular peak flow checking helpful.

Microspirometry

Simple inexpensive hand held spirometers, programmed at each use with the patient's age height and gender can give good accurate readings of FEV₁ (forced expiratory volume in 1 second), and express this as percent predicted. The simplest and cheapest devices measure FEV₁ only but hand held meters are now available for less than £150 that provide FEV₁, FVC and FEV₁/FVC ratio, together with apps which provide instructions, assess quality and reproducibility of efforts and keep records of results which can be stored and transmitted.

The necessary expiratory manoeuvre and the correct use of the instrument are more demanding than measurement of peak flow, but it is possible both to teach their use and to supervise their performance by video link.

These instruments are not – in an ideal world – a substitute for full diagnostic spirometry in COPD. But until timely access to full diagnostic spirometry is possible it is much better to obtain results from microspirometry than to rely solely on clinical features for a diagnosis of COPD. It would be possible for practices to organise a system of loan and return of microspirometers – with appropriate sterilisation of the equipment between patients.



The simplest microspirometers are useful for screening adults – especially symptomatic older smokers – for possible COPD. An FEV₁ of 80% predicted or less should prompt consideration of full diagnostic spirometry. Note that if COPD is being considered as a diagnosis then screening or diagnostic spirometry should be done at least 4–6 weeks after the resolution of acute symptoms. If asthma is suspected then what you need is a microspirometry at the time the patient is symptomatic, with measurement of FEV₁ before and after treatment.

In the assessment of asthma, a rise in FEV₁ of 12% and at least 200ml with time or treatment is suggestive of asthma. An increase of 400ml or more in FEV₁ is strongly suggestive of asthma.² Here the key difference is that measurements both before and after treatment or resolution of acute symptoms provide the best information.

Conclusion

Asthma diagnosis is difficult, and a matter of controversy. There are concerns about over-diagnosis – although delayed diagnosis is also still a problem. The well established BTS/SIGN guideline, updated in 2019, contains a comprehensive discussion of the approach to diagnosis and recommends spirometry as the preferred test of airways obstruction.³ The much criticised NICE guideline on diagnosis and monitoring of asthma² suggests a different approach involving measurement of FeNO in addition to spirometry for (nearly) all. This was impracticable even before the pandemic. Both guidelines

retain a place for peak flow measurements but relegate these to a subsidiary role. However, spirometry is very often normal in suspected asthma in primary care. The quality of full diagnostic spirometry in primary care is variable and there is a substantial training need if it is to be easily available to all – a highly desirable aim. Issues of training and of the availability of quality assured spirometry have prompted the development of community diagnostic hubs for the provision of this and other diagnostic services, but this is work in progress and such hubs are not yet available in many areas, while waiting times for secondary care services are long.

Peak flow monitoring – cheap, (relatively) simple and easily repeatable – and microspirometry – should both play an important role in respiratory diagnosis. Their importance is increased in the circumstances of the ongoing pandemic of COVID-19. All primary health care professionals involved in respiratory care should know how to teach their use and interpret their results.

References

1. Baxter N, Lonergan T *et al*. Diagnostic work up of the patient presenting with respiratory symptoms during the COVID-19 pandemic. September 2020. Primary Care Respiratory Society UK. <https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/Diagnosis-asthma-COPD-during-Covid-19-v2-17-September-2020.pdf> Last accessed 6 November 2020
2. Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80] Published date: 29 November 2017 Last updated: 12 February 2020 NICE asthma guideline.
3. BTS/SIGN British Guideline on the Management of Asthma <https://www.brit-thoracic.org.uk/quality-improvement/>
4. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. *BMJ* 2003;327 doi: <https://doi.org/10.1136/bmj.327.7416.653>

Date of Preparation: March 2017 V1; Revised September 2020 V2